Barkley Pathophysiology, Pharmacology, and Physical (3P) Assessment Practice Exam

Fluvoxamine is classified as a selective serotonin reuptake inhibitor (SSRI) and is particularly effective in treating obsessive-compulsive disorder (OCD). Its primary mechanism of action involves the inhibition of the reuptake of serotonin (5-HT) in the synaptic cleft. By blocking the serotonin transporter (SERT), fluvoxamine increases the availability of serotonin in the brain, which is thought to alleviate the symptoms associated with OCD.

The enhancement of serotonin signaling is crucial, as deficits in serotonin function have been implicated in mood and anxiety disorders, including OCD. By modulating serotonergic pathways, fluvoxamine helps to reduce the frequency and intensity of obsessive thoughts and compulsive behaviors typically experienced by individuals with OCD. This pharmacological action differentiates it from other classes of medications that may affect dopamine or norepinephrine pathways, which are not primarily involved in the therapeutic efficacy for OCD.

Overall, the selectivity for serotonin reuptake makes fluvoxamine particularly suited for managing OCD symptoms, positioning it as a cornerstone in the pharmacological treatment of this disorder.